Lv11
48 积分 2026-06-05 加入
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
38分钟前
待确认
Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and management
11天前
已完结
The next generation of antibody–drug conjugates
11天前
已完结
Killing resistant tumors with a click
11天前
已完结
Clinical toxicity of ADCs and ICI-ADC combinations: mechanisms, patterns and management
1个月前
已完结
The next generation of antibody-drug conjugates
1个月前
已完结
Antibody-Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors
1个月前
已关闭
Antibody-Drug Conjugates Against Multidrug-Resistant Cancers: Biomarker-Guided Patient Selection, Payload Engineering, Linker Chemistry, and Bystander Effects
1个月前
已完结
Linker Chemistry in Antibody-Drug Conjugates: Current Strategies, Clinical Pharmacokinetic Analyses, and Linker-Free Outlooks
1个月前
已完结
h3B7A-LDM, a novel anti-mesothelin antibody-drug conjugate with the potential to induce antitumor immunity, shows potent efficacy against solid tumors
1个月前
已完结
皖公网安备34019202002308
